Abstract
Introduction
Genetic loss-of-function screens are used to systematically identify genes important for cellular viability and genetic interactions in model organisms (Costanzo et al. 2010; Berns et al. 2004 ) . Traditionally these have been performed with RNA interference (RNAi) (Marcotte et al. 2016; McDonald et al. 2017; Tsherniak et al. 2017) , although its application to mammalian cells have been hampered by incomplete protein depletion and off-target effects (Jackson et al. 2006; Echeverri et al. 2006) . The advent of CRISPR-Cas technologies facilitates genome engineering of human cells by addressing many of the limitations of RNAi (Shalem et al. 2014; Wu et al. 2014; Wang et al. 2014; Koike-Yusa et al. 2014 ) and increases capacity to identify genes essential for cellular fitness (Morgens et al. 2016; Evers et al. 2016 ) . In cancer cell lines, CRISPR-Cas9 dropout screens have been integrated with genomic data-sets to propose novel therapeutic targets (Tzelepis et al. 2016; Marcotte et al. 2016; Hart et al. 2015; Wang et al. 2017 ) . Tumour cells genetic instability induces synthetic-lethal dependencies on genes that otherwise have no impact on cellular fitness (Kaelin 2005) . The concept of synthetic lethality has been used to selectively target cancer cells (Muller et al. 2012) , translating into improvements in patient care (Farmer et al. 2005) . Targeted high-throughput loss-of-function screens provide a systematic way to identify these types of cellular dependencies.
Gene copy-number changes, despite being rare and often detrimental in normal healthy cells (Itsara et al. 2009) , are one of the most frequent types of genomic alterations in cancers (Beroukhim et al. 2010) . They are of particular importance when analysing CRISPR-Cas9 dropout experiments, since targeting genomic regions that are copy-number amplified induces strong DNA damage responses that lead to cell cycle arrest and cell death (Aguirre et al. 2016; Munoz et al. 2016 ) . The effect is gene-independent and ubiquitous across cancer types. This increases the false-positive rate for detecting loss of fitness (LOF) genes when interpreting CRISPR-Cas9 experiments that target amplified regions. We and others developed computational methods to account for this systematic bias (Meyers et al. 2017; Iorio et al. 2017 ) . Some of these approaches are guided by knowledge of gene copy-number values, which on average are proportional to the non-specific LOF effect of CRISPR-Cas9 targeting.
Nonetheless, the strength of this association varies significantly between cell lines and amplicons with similar copy-number, and is completely absent in some cases (Iorio et al. 2017 ) . This indicates that other cellular features besides copy-number influence the non-specific CRISPR-Cas9 LOF effects.
Cancer cells undergo extensive genomic alterations (Sudmant et al. 2015; Li et al. 2017; Glodzik et al. 2017 ) but their impact on CRISPR-Cas9 targeting and response is poorly understood. Here, we combined CRISPR-Cas9 screens with whole-genome sequencing (WGS) and DNA SNP6 copy number arrays to investigate the impact of structural variation (SV) on CRISPR-Cas9 response. We find that the non-specific LOF effect of CRISPR-Cas9 screens when targeting copy-number amplified regions is specific to tandem duplications, in stark contrast to amplifications arising from chromosomal duplication. Considering cell ploidy provides more robust associations between copy-number changes and CRISPR-Cas9 LOF effects. Based on these observations, we identify cancer synthetic-lethal vulnerabilities that are elicited by targeting tandem amplified regions with CRISPR-Cas9.
Results

Increased cell ploidy buffers non-specific CRISPR LOF effects
We considered genome-wide CRISPR-Cas9 knockout screens performed in 17 different tumour types comprising 163 cancer cell lines which have been previously genomically characterised, i.e. copy-number and gene-expression (Supplementary Figure 1A) (Supplementary Table S1 ) (Behan et al. n.d.) . Gene-essentiality fold-change profiles were estimated for a total of 17,234 genes, each targeted on average by 5 single-guide RNAs (sgRNAs). For the majority of the cell lines, 3 technical replicates were performed and gene log-fold change values had an average Pearson correlation (R) of 0.78. Genes previously defined as essential for cellular viability (Hart et al. 2015) were robustly recapitulated across all samples (mean Area Under Recall Curve (AURC) = 0.88), and as previously described (Munoz et al. 2016 ) non-detrimental genes displayed a small enrichment for positive fold-changes (mean AURC = 0.42) (Supplementary Figure 1B) . Consistent with previous findings (Aguirre et al. 2016; Munoz et al. 2016) , sgRNAs targeting copy-number amplified genes were amongst those with the strongest LOF effects in the screen, even when not expressed ( Figure 1A ). Importantly, we observed that enrichment for LOF of sgRNA targeting amplicons varies significantly between cell lines ( Figure 1B ). This suggests that other factors, besides copy-number, contribute to the LOF effects found in CRISPR-Cas9. We investigated if cell ploidy differentiates cell line responses to CRISPR-Cas9 and observed that cells with higher ploidy display significantly lower fitness reduction for sgRNAs targeting copy-number amplified regions ( Figure 1C ). The majority of the variation observed in each copy-number group defined in ( Figure 1B Figure 1C) . Overall, these results show that absolute copy-number profiles need to be analysed together with cell ploidy, or chromosome copies, to model accurately the non-specific fitness reduction in CRISPR-Cas9 gene knockout experiments.
CRISPR-Cas9 LOF is specific to tandem duplications
Considering that chromosome aneuploidy is common in cancer cells, we set to analyse the implication of SV in CRISPR-Cas9 screens. To that end, we utilised WGS data of 6 breast cancer cell lines with a matched normal to call somatic SVs, such as tandem duplications, translocations, deletions and inversions, using BRASS (BReakpoint AnalySiS) (Glodzik et al. 2017) . Tandem duplications were the most frequent type of rearrangements across the 6 cell lines (Figure 2A ), recapitulating previous observations that this is a frequent event in breast cancers (McBride et al. 2012; Glodzik et al. 2017) . Utilising a statistical framework, we then searched for associations between SVs and CRISPR-Cas9 LOF effects. SVs were most informative of CRISPR-Cas9 response when accompanied by copy-number alterations, with strong LOF falling within tandem duplications (Figure 2 Figure 2D) . These examples show how SVs, specifically tandem duplications, result in copy-number alterations that lead to non-specific LOF effects in CRISPR-Cas9 experiments. Table 2 ). This was necessary because WGS was not available for most cell lines. The ratio encompasses three scenarios: a value (i) less than 1 represents a gene depletion, (ii) equal to 1 represents either a normal diploid chromosome with 2 copies of the gene or deletions/amplifications that are consistent in the gene and the chromosome; (iii) greater than 1 represents genes that have been amplified more than the chromosome to which they map, likely representing tandem or interspersed duplications. This ratio allows us to separate gene duplications that originate from whole chromosome/genome duplication from those arising from smaller tandem amplifications, which we hypothesize induces stronger CRISPR-Cas9 LOF effects.
Non-expressed genes with copy-number ratios greater than 1 showed strikingly higher LOF effects ( Figure 3B , Supplementary Figure 3A) . Ratios greater than 4 displayed among the strongest LOF effects captured in the screen (mean log2 fold-change < -1) (Supplementary Figure 3A) . The distribution of the copy-number ratios across all cell lines was centered around 1 confirming that the vast majority of copy-number alterations originate from whole chromosome duplications (Supplementary Figure 3B) . Notably, we observed thousands of occurrences of highly amplified genes with a copy-number ratio close to 1 which displayed almost no CRISPR-Cas9 LOF effects ( Overall, these results are important for the analysis of CRISPR-Cas9 datasets showing that non-specific LOF effects induced by targeting of copy-number amplified regions are specific to tandem duplicated regions, while copy-number amplifications originating from chromosome duplication have little to no effect.
Figure 3. Gene copy-number ratio association with CRISPR-Cas9 loss of fitness effect. (A) Diagram of the different genomic rearrangements captured by the gene copy-number ratio and their potential effect in CRISPR-Cas9 response. (B) Enrichment of high copy-number ratios to strong CRISPR-Cas9 LOF effects. Recall curves of non-expressed genes grouped by their copy-number ratio profile across CRISPR-Cas9 fold-changes. (C) Matrix of gene and chromosome copies. The total number of events in each condition with a copy number ratio equal to 1 (rounded to nearest whole number) are shown, and (D) represents the mean gene-level CRISPR-Cas9 fold-change (log2) in the respective group.
CRISPR-Cas9 collateral vulnerabilities in cancer cells
Our finding that targeting tandem amplifications with CRISPR-Cas9 induces a potent and specific LOF effect could facilitate exploitation of this mechanism to develop targeted cancer therapies. Cancer cells generally display profound alterations of their karyotype with complex genomic rearrangements, which are rare in healthy cells. Targeting copy number amplified regions with CRISPR-Cas9 to induce synthetic-lethal effects has been postulated (Aguirre et al. 2016) . Hence, here we systematically investigate the prevalence of collateral vulnerabilities and refine this concept to targeting tandem duplicated genomic regions with CRISPR-Cas9 reagents, as these are likely to have strong and selective LOF effects in cancer cells. We focus on tandem duplicated regions, which likely but not necessarily contain oncogenes, and non-expressed genes to limit potential toxicity in healthy tissue ( Figure 4A ).
We refer to this concept as CRISPR-Cas9 collateral essentiality.
We systematically searched the 163 cancer cell lines for collateral essentialities and used stringent filters to focus on genes that: (i) have strong LOF effects; (ii) are genomically colocalized with a high copy-number ratio gene; and (iii) are not expressed across the majority of the cell lines of the same tissue. A total of 223 CRISPR-Cas9 collateral essentialities were identified (Supplementary Table 3 ) (194 unique genes), 59.2% of these involved associations with 53 cancer driver genes identified in COSMIC (Forbes et al. 2015) . Collateral essentialities were identified in 24.5% of the screened cell lines (40 cell lines across 9 different tumour types), demonstrating the general nature of this mechanism ( Figure 4B ).
Among the most frequent collateral essentialities was NEUROD2 associated with ERBB2 amplifications present in 4 cell lines ( Figure 4C ), and MRGPRD associated with CCND1 amplifications present in 3 cell lines (Supplementary Figure 5A, B) . NEUROD2 is involved in neuronal differentiation, mainly expressed in the brain (Supplementary Figure 5C) , and frequently amplified in breast tumours (Supplementary Figure 5D) . Focusing on the cell line with the strongest amplification of ERBB2 and strongest LOF response to NEUROD2 knockout, i.e. breast carcinoma cell line AU565 , we confirmed that ERBB2 and NEUROD2 are co-genomically amplified ( Figure 4D) . Notably, gene copy-number ratio separates better the CRISPR-Cas9 LOF responses compared to the absolute copy-number ( Figure 4C ), suggesting that some cell lines do not respond to NEUROD2 knockout likely due to ERBB2 amplifications arising from chromosome duplications. Together, these results illustrate the concept of selectively targeting cancer cells with potentially reduced toxicity by exploiting CRISPR-Cas9 collateral essentiality. 
Discussion
In this study, we demonstrate that copy-number amplifications lead to non-specific CRISPR-Cas9 LOF effects if originating from tandem duplications. In contrast, no impact is observed from gene amplifications associated with increased cell ploidy. We devised a gene copy-number metric, normalised by chromosome copy-number, that greatly improves the ability to classify which copy-number amplifications will result in a LOF bias in CRISPR-Cas9 experiments. Notably, our findings were recapitulated when considering only non-expressed genes, emphasising that the LOF bias is not due to a potential biological function of the genes.
Combining the copy-number ratios, WGS and FISH experiments, we validated that tandem duplications are the most frequent SVs associated with CRISPR-Cas9 non-specific deleterious effects. Nonetheless, we cannot exclude that other events might also play a role. In particular, extrachromosomal DNAs (ecDNA) have been found widespread in cancer (Stephens et al. 2011; Turner et al. 2017) and are tandem duplicated rich DNA sequences, although we did not observe any evidence of ecDNAs in the cell lines analysed with FISH.
We hypothesise that CRISPR-Cas9 non-specific LOF effects in copy-number amplified regions is buffered if Cas9 double-strand breaks (DSB) are spread across several chromosomes (Supplementary Figure 7) . We expect that nonhomologous end joining (NHEJ) repair of clustered DSBs can lead to large deletions and changes in copy-number, thereby inducing strong DNA damage and LOF responses. Hence, chromosomal structural alterations such as tandem duplications can determine CRISPR-Cas9 response. Moreover, this presents evidence that structural rearrangements can impact the functioning of DNA damage repair mechanisms with important implications in cellular phenotype.
Tandem duplications are among the most frequent structural rearrangements in cancer (Li et al. 2017 ) indicating that our findings are of general importance when designing and interpreting CRISPR-Cas9 experiments. Specifically, targeting genes that reside within regions of tandem duplication, whether knocking out individual genes, performing genetic screens using a library of sgRNAs, or performing specific gene edits, will lead to strong non-specific LOF effects. Computational methods such as Crispy and others (Iorio et al. 2017) can efficiently correct for this bias in CRISPR-Cas9 screens. However, this is unlikely to be possible for many studies, for example the common scenario of a single gene knockout or alteration in individual cell lines. In these cases, information about gene copy number, cell line ploidy and ideally SV information should be incorporated. We expect that the bias in CRISPR-Cas9 data described here is a general phenomenon and consequently will be observed in other cancer cell models such as patient-derived xenografts and organoids, and potentially also present in other types of CRISPR-Cas based systems that introduce DNA double-strand breaks.
Collateral vulnerabilities are typically defined as cancer-specific therapeutic vulnerabilities offered by passenger gene deletion or inactivation of non-tumour suppressor genes, and this is a well-established paradigm in oncology. Here we extend this concept to cancer-specific vulnerabilities that can be exploited through CRISPR-Cas9 targeting of tandem duplicated regions of cancer genomes, and demonstrate that this a general phenomenon in cancer cells. This theoretical approach could be applied based on the detailed analysis of an individual genome, or by targeting regions of recurrent tandem duplication (Glodzik et al. 2017) .
We have examined the application to non-expressed genes, but this may be effective when targeting non-genic regions, further reducing the risk of toxicity to healthy cells. CRISPR-Cas9 applications to gene editing and personalised medicine are in their infancy but quickly progressing, and promising results have been obtained by injecting localised viral vectors expressing CRISPR-Cas (Xue et al. 2016) . Nonetheless, important hurdles remain with respect to delivery, efficiency and safety before this approach could be considered clinically. In summary, this work provides new insights into CRISPR-Cas9 mediated LOF effects, with implication for the use of CRISPR-Cas9 gene-editing, and points to CRISPR-Cas9 collateral essentiality as an approach to develop tumour cell specific therapies.
Materials and Methods
Processing of CRISPR-Cas9, SNP6 and RNA-seq samples
A CRISPR-Cas9 library containing 95,994 sgRNAs was utilised (Koike-Yusa et al. 2014; Tzelepis et al. 2016) to screen the loss of fitness (LOF) impact of knocking-out each 17,234 genes across 163 cell lines as described here (Behan et al. n.d.) . Raw sequence counts of each sgRNA were corrected by library size in each sample using median-of-ratios method, similar to DESeq2 (Anders & Huber 2010) . Only replicates with a Pearson correlation (R) coefficient greater than 0.7 were considered. Non-targeting plasmid control sample was used and sgRNAs with lower than 30 counts were discarded. Log2 sgRNA fold-changes were estimated between samples and the plasmid control. Gene level estimates of the fold-changes were calculated by averaging all mapping sgRNA fold-changes. Single nucleotide polymorphism (SNP) array hybridization using the Affymetrix SNP6.0 platform was performed according to Affymetrix protocols. Segment copy-number variants were obtained using PICNIC (Greenman et al. 2010 ) as previously described (Iorio et al. 2016 ) . RNA-seq experiments for CRISPR-Cas9 profiled cell lines were assembled from multiple data-sets (Garcia-Alonso et al. 2017 ) . To minimise technical bias, all samples were processed with the same pipeline, iRAP (Fonseca et al. 2014) , to obtain raw counts. Genes with Reads Per Kilobase per Million (RPKM) with zero counts were termed as non-expressed in the particular sample.
Chromosome harvest and fluorescence in situ hybridisation (FISH)
Metaphase chromosomes were harvested from the cancer cell lines after incubation with 0.05 g/ml of colcemide (Thermo-Fisher) for 2-3 h. Subsequently, cells were treated with a buffered hypotonic solution (0.4% KCl in 10 mM HEPES, pH7.4) for 8 -12 min at 37°C and fixed with 4:1(v/v) methanol:glacial fixative. The human fosmid clone WI2-1694H13 was labelled with green-dUTP as described in (Stephens et al. 2011) . Human 24 colour FISH (M-FISH) probe preparation and slides treatments followed (Agu et al. 2015) with slight modifications.
Freshly-prepared metaphase slides were immersed in acetone for 10 min and then baked at 62 C for 1 hour. Slides were denatured in an alkaline denaturation solution (0.5 M NaOH, 1.5 M NaCl, Sigma-Aldrich) for 9-10 min. Metaphases were examined with a Zeiss AxioIamger D1 fluorescence microscope. FISH images were captured using the SmartCapture software (Digital Scientific UK) and karyotyped using the SmartType Karyotyper software (Digital Scientific UK). Ten metaphases for each sample were analysed by M-FISH.
Whole-genome sequencing
DNA of 6 cancer cell lines and 6 EBV derived matched normal cell lines were obtained and sequenced with massively parallel Illumina sequencing technology (EGAD00001004124) and aligned to the human reference genome GRCh37 using Burrows-Wheeler Aligner (v0.5.9) ( 
Crispy Python module to identify genomic determinants of CRISPR-Cas9 screens
Crispy is a flexible tool to identify systematically associations between multiple types of genomic alterations and CRISPR-Cas9 response. Gaussian processes regressions implemented on scikit-learn Python module (v0.19.1) (Pedregosa et al. 2011) were used, specifically a squared-exponential kernel with a length scale (ө) hyperparameter varying between 1e-5 and 10 is used. A constant (σ) and noise (ψ) kernels are also added: Figure 6B ) and preserved the capacity to identify essential genes (Supplementary Figure 6D) .
Moreover, the ploidy association with LOF responses was greatly reduced after Crispy correction (Supplementary Figure 6C) .
Gene copy-number ratios
Gene copy-number ratios, i.e. number of absolute gene copies divided by the number of copies of the respective chromosome, are performed for all protein-coding genes annotated in the human GRCh37 reference assembly. Segment absolute copy-numbers are mapped to the assembly using BEDtools (v2.27.1) (Quinlan & Hall 2010) and pybedtools (v0.7.10) (Dale et al. 2011 ) . Gene and chromosome absolute copy-number values are estimated by taking the copy-number weighted mean of all the mapping segments weighted by their size. Gene copy-number ratios across the 163 cell lines are available in Supplementary Table 2 .
To verify that high copy-number ratios represent strong focal chromosome amplifications we applied FISH and probed the location of the frequently and highly amplified oncogene MYC .
We chose 2 cell lines (HCC1954 and NCI-H2087) with high MYC absolute copy-number (9 and 7, respectively) but discordant copy-number ratios (1.58 and 4.05, respectively) due to different ploidy. Consistent with our hypothesis, MYC amplifications in the tetraploid cell line (HCC1954) displays a small level of tandem duplications of MYC while the majority of the copies were spread across derivatives of chromosome 8 (Supplementary Figure 3D) . In contrast, in the diploid cell line (NCI-H2087) MYC copies were mostly concentrated in one arm of a derivative of chromosome 8 (Supplementary Figure 3F) . A control triploid cell line (LS1034) with diploid MYC and rounded copy-number ratio 1 was analysed and corroborated our prediction that chromosome 8 is mostly diploid and contains 2 copies of MYC (Supplementary Figure 4A) .
Collateral essentialities
Collateral essentialities were identified across all 163 cancer cell lines using CRISPR-Cas9 log2
fold-changes, SNP6 estimated copy-number ratios and RNA-Seq defined non-expressed genes. Firstly, tandem amplified genes across cell lines were defined as those with a copy-number ratio greater than 2. Secondly, non-expressed essential genes were defined in each cell line as those genes with a RPKM < 1 and a CRISPR-Cas9 log fold-change lower than the mean of known essential genes (Hart et al. 2015 ) . An off-set of 25% of the mean log fold-change of essential genes was used in order to capture genes with strong LOF effects that are not as strong as essential genes. In order to exclude genes with a strong LOF across most of the cell lines and focus on those that are tissue or subtype specific, we excluded genes that had stronger LOF effects than the offsetted essential genes in more than 15% of the total cell lines (24 cell lines). Lastly, collateral essentialities were defined as pairs of genes that in the same cell line one is tandem amplified and the other is non-expressed and essential. Only gene pairs that are on the same chromosome and genomically co-localised were considered. The genomic distance between the two genes has to be lower than 1 Mb. Vulnerable cell lines were defined as those with at least one collateral essentiality and for which the collateral essential gene (non-expressed and essential) was not expressed in at least 50% of the cell lines from the same tissue, thus reducing tissue specific essential genes and potential cytotoxic effects.
Copy-number amplification data for the relevant genes in tumour samples was obtained from cBioPortal (Cerami et al. 2012; Gao et al. 2013 
Code availability
Crispy is a Python module ( https://github.com/EmanuelGoncalves/crispy ) and its code is distributed under the open-source 3-Clause BSD License.
Supplementary Figures
Supplementary Figure 1 . Screen, quality control and loss of fitness bias of CRISPR-Cas9 (Hart et al. 2015) . 
fold-changes. (A) Number of cell lines screened per cancer type. (B) Recall curves of previously defined core-essential (top) and non-essential (bottom) genes
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